About Us

Lisa brings 20 years of clinical trials and drug development experience spanning small molecules and biologics, heavily in oncology. She has extensive First-In-Human, Breakthrough, End-Of-Phase-II and NDA/BLA/MAA experience including many primary roles. She has held increasing leadership with diversity making her well-rounded in expertise. Lisa served as Head of Clinical Sciences (Early Clinical Development), Oncology, Servier Pharmaceuticals; SVP, Head of Clinical Development, Bicycle Therapeutics; VP, Head of Clinical Development, Syros Pharmaceuticals; Global Head of Clinical Pharmacology, EMD Serono (Merck KGaA); Global Clinical Lead, first approval of Bavencio, EMD Serono (Merck KGaA); Global Head of Clinical Pharmacology, Vertex Pharmaceuticals; Global Clinical Lead, Vertex Pharmaceuticals; Clinical Pharmacologist, Merck & Co (MSD); Global Clinical Lead, Bristol Myers Squibb.

Highlights: US and EU first approvals of Bavencio (PDL1 checkpoint inhibitor); 41bb checkpoint inhibitor early development; DNA damage repair inhibitors ATR, ATM and DNA-PK First-In-Human; End-Of-Phase II package MET inhibitor tepotinib; First-In-Human studies IDO and TGFβ2R-avelumab fusion; CDK7 early development; EphA2 and Nectin ADC-like peptide conjugates First-In-Human; Bcl2 and MCL1 pro-apoptosis early development; dual checkpoint inhibitor, innate immune modulator and other oncology targets.

Expertise in Breakthrough, Scientific Advice, IND, CTA, End-Of-Phase II and BLA/NDA/MAA